The diversity of the immune response to the A2 domain of human factor VIII

Blood

Volumn 121, Issue 14, 2013, Pages 2785-2795

  Markovitz, Rebecca C ^a   Healey, John F ^a   Parker, Ernest T ^a   Meeks, Shannon L ^a   Lollar, Pete ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; EPITOPE; HUMAN A2 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEMOPHILIA A; IMMUNE RESPONSE; LIGHT CHAIN; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; CROSS REACTION; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; SWINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; SWINE; THROMBIN;

MLCS; MLOWN;

EID: 84878218869     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-456582     Document Type: Article

References (45)

1. Lusher JM, Arkin S, Abildgaard CF, et al. Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med. 1993;328(7):453-459.
2. Bray GL, Gomperts ED, Courter S, et al. The Recombinate Study Group. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994;83(9):2428-2435.
3. Lusher JM, Lee CA, Kessler CM, et al. ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9(1):38-49.
4. Zaitseva I, Zaitsev V, Card G, et al. The X-ray structure of human serum ceruloplasmin at 3.1 Angstroms: nature of the copper centres. J Biol Inorg Chem. 1996;1:15-23.
5. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988; 263(21):10451-10455.
6. Lollar P, Parker ET, Curtis JE, et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest. 1994;93(6):2497-2504.
7. Fay PJ, Beattie T, Huggins CF, et al. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994;269(32): 20522-20527.
8. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem. 1990;265(3):1688-1692.
9. Prescott R, Nakai H, Saenko EL, et al. Recombinate and Kogenate Study Groups. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997;89(10):3663-3671.
10. Scandella D, Timmons L, Mattingly M, et al. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost. 1992;67(6): 665-671.
11. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270(24): 14505-14509.
12. Healey JF, Parker ET, Barrow RT, et al. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost. 2007; 5(3):512-519.
13. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991;266(14):8957-8962.
14. Parker ET, Doering CB, Lollar P. A1 subunitmediated regulation of thrombin-activated factor VIII A2 subunit dissociation. J Biol Chem. 2006; 281(20):13922-13930.
15. Summers RJ, Meeks SL, Healey JF, et al. Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. Blood. 2011;117(11):3190-3198.
16. Kasper CK, Aledort LM, Counts RB, et al. Letter: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(3): 869-872.
17. Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost. 2006;4(10):2223-2229.
18. Lubin IM, Healey JF, Scandella D, et al. Elimination of a major inhibitor epitope in factor VIII. J Biol Chem. 1994;269(12):8639-8641.
19. Shen BW, Spiegel PC, Chang C-H, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008;111(3): 1240-1247.
20. Ngo JC, Huang M, Roth DA, et al. Crystal structure of human factor VIII: Implications for the formation of the factor IXa-factor VIIIa complex. Structure. 2008;16(4):597-606.
21. Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. In: Hoyer LW, ed. Factor VIII Inhibitors. New York, NY: Alan R. Liss; 1984:73-85
22. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem. 1990;265(29): 17854-17858.
23. Pierres M, Devaux C, Dosseto M, et al. Clonal analysis of B- and T-cell responses to Ia antigens. I. Topology of epitope regions on I-Ak and I-Ek molecules analyzed with 35 monoclonal alloantibodies. Immunogenetics. 1981;14(6): 481-495.
24. Morris CA, Underwood PA, Bean PA, et al. Relative topography of biologically active domains of human vitronectin. Evidence from monoclonal antibody epitope and denaturation studies. J Biol Chem. 1994;269(38):23845-23852.
25. Corti D, Suguitan AL Jr, Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010; 120(5):1663-1673.
26. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850-856.
27. de Silva HD, Saleh S, Kovacevic S, et al. The antibody response to Plasmodium falciparum merozoite surface protein 4: Comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. Malar J. 2011;10: 266.
28. Parra GI, Abente EJ, Sandoval-Jaime C, et al. Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. J Virol. 2012;86(13): 7414-7426.
29. Lelli D, Moreno A, Brocchi E, et al. West Nile virus: Characterization and diagnostic applications of monoclonal antibodies. Virol J. 2012;9:81.
30. Meeks SL, Healey JF, Parker ET, et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood. 2007;110(13):4234-4242.
31. Ling M, Duncan EM, Rodgers SE, et al. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost. 2003;1(12):2548-2553.
32. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991;266(30):20139-20145.
33. Leyte A, Mertens K, Distel B, et al. Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J. 1989;263(1):187-194.
34. Andersson LO, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J. 1981;200(1):161-167.
35. Lajmanovich A, Hudry-Clergeon G, Freyssinet JM, et al. Human factor VIII procoagulant activity and phospholipid interaction. Biochim Biophys Acta. 1981;678(1):132-136.
36. Arai M, Inaba H, Higuchi M, et al. Direct characterization of factor VIII in plasma: Detection of a mutation altering a thrombin cleavage site (arginine-372-histidine). Proc Natl Acad Sci U S A. 1989;86(11):4277-4281.
37. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of antihemophilic factor (factor VIII). Proc Natl Acad Sci U S A. 1988;85(8):2429-2433.
38. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem. 1999;274(42):29826-29830.
39. Donath MJ, Lenting PJ, Van Mourik JA, et al. Kinetics of factor VIII light-chain cleavage by thrombin and factor Xa. A regulatory role of the factor VIII heavy-chain region Lys713-Arg740. Eur J Biochem. 1996;240(2):365-372.
40. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci U S A. 1989;86(17):6508-6512.
41. Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995;270(15): 8546-8552.
42. Aly AM, Arai M, Hoyer LW. Cysteamine enhances the procoagulant activity of factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine). J Clin Invest. 1992;89(5): 1375-1381.
43. Arai M, Higuchi M, Antonarakis SE, et al. Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A. Blood. 1990;75(2): 384-389.
44. Meeks SL, Healey JF, Parker ET, et al. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood. 2008;112(4):1151-1153.
45. Sachais BS, Litvinov RI, Yarovoi SV, et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood. 2012;120(5): 1137-1142.